IN BRIEF: Synairgen Recruits Covid-19 Patients Into Phase II Trial
IN BRIEF: Synairgen Recruits Covid-19 Patients Into Phase II Trial
Read moreMon, 15th Feb 2021 11:57
IN BRIEF: Synairgen Recruits Covid-19 Patients Into Phase II Trial
Read moreSynairgen Doses First Patient In Covid-19 Treatment Trial
Read moreBy Nancy LapidJan 11 (Reuters) - The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.Half a year later, COVID-19 pat...
Read moreLONDON MARKET MIDDAY: FTSE 100 Rises As Crunch Brexit Talks Dent Pound
Read moreSynairgen Gets Fast Track Designation From US FDA For Covid-19 Vaccine
Read more(Sharecast News) - Respiratory drug development company Synairgen updated the market on its phase 3 trial design evaluating SNG001 as a treatment for patients with Covid-19 on Friday, as well as positive progress on its regulatory path.
Read morefinnCap Interim Profit More Than Doubles; Chair To Step Down
Read more(Sharecast News) - Synairgen shares surged on Friday after data from trials of its inhaled Covid-19 treatment, SNG001, published in The Lancet Respiratory Medicine, showed positive results in hospitalised patients.
Read moreSynairgen Drug Helps Recovery In Hospitalised Covid-19 Patients
Read moreUK TRADING UPDATE SUMMARY: Sensyne App Used In Oxford Covid Study
Read moreSynairgen Raises GBP80 Million In Placing, To Launch Open Offer
Read moreIN BRIEF: Synairgen Looks To Raise GBP80 Million For SNG001 Trial
Read moreSynairgen Progresses Covid-19 Treatment As Expenses Increase
Read moreIN BRIEF: Synairgen Makes Inhaled Interferon Beta Patent Application
Read more(Sharecast News) - Respiratory drug development company Synairgen updated the market on its intellectual property for the wholly-owned inhaled interferon beta asset 'SNG001' on Wednesday.
Read more